7200AA21RFA00005: Discovery & Exploration of Emerging Pathogens – Viral Zoonoses (DEEP VZN)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Agency for International Development notices from 2021.
Agency for International Development offered grants of up to $125 million to any type of organization. It expected to make one award. Applications closed on June 17, 2021.
From the official notice on Grants.gov, last changed May 28, 2021. Checked November 7, 2026.
- Award ceiling$125 million
- Expected awards1
- Cost sharingRequired
- Funding typeCooperative Agreement
Key dates
| Posted | May 18, 2021 |
|---|---|
| Deadline | June 17, 2021 |
| Archived by Grants.gov | July 17, 2021 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Past USAID Foreign Assistance for Programs Overseas awards averaged $8.7 million; this notice allows up to $125 million per award.
- Most of the program's money (54% over five years) went to nonprofits.
- The notice requires cost sharing or matching funds, so you must contribute part of the project cost.
What the grant funds
The United States Agency for International Development (USAID) is seeking applications for a cooperative agreement from qualified entities to implement the Discovery & Exploration of Emerging Pathogens – Viral Zoonoses (DEEP VZN) program. Eligibility for this award is not restricted. Deadline for Questions: May 20, 2021; 1:00 p.m., Washington, DC Time Closing Date: June 17, 2021 Closing Time: 1:00 p.m., Washington, DC Time
Who has won USAID Foreign Assistance for Programs Overseas grants before
From fiscal 2021 to 2025, USAID Foreign Assistance for Programs Overseas (98.001) awarded $37 billion across 4,233 grant awards, an average of $8.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Miscellaneous Foreign Awardees | District of Columbia | 489 | $6.9 billion |
| Family Health International | North Carolina | 91 | $2.1 billion |
| Catholic Relief Services - United States Conference of Catholic Bishops | Maryland | 128 | $1.2 billion |
| Save the Children Federation, Inc. | Connecticut | 100 | $814 million |
| Research Triangle Institute | North Carolina | 33 | $756 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is 7200AA21RFA00005 still open?
No. It closed on June 17, 2021.
Who can apply for Discovery & Exploration of Emerging Pathogens – Viral Zoonoses (DEEP VZN)?
Agency for International Development accepted applications from any type of organization.
What is the deadline for Discovery & Exploration of Emerging Pathogens – Viral Zoonoses (DEEP VZN)?
Closed June 17, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $125 million each.
Who has won USAID Foreign Assistance for Programs Overseas grants before?
The largest recipients over five fiscal years were Miscellaneous Foreign Awardees, Family Health International, Catholic Relief Services - United States Conference of Catholic Bishops. The program made 4,233 awards worth $37 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)